Modified 5'UTR
Modified 5'UTRs with Kozak consensus sequences and point mutations enhance protein translation efficiency in mRNA therapeutics by reducing secondary structures, addressing the regulatory challenges of existing 5'UTRs.
Patent Information
- Application Number
- JP2024531196
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-30
- Filing Date
- 2022-11-29
- Publication Date
- 2024-11-14
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing mRNA therapeutics face challenges in efficiently translating proteins due to the regulatory role of the 5' untranslated region (UTR), which affects translation rate and transcript degradation, necessitating improved design and discovery of 5'UTRs for enhanced manufacturability and dosing.
Development of modified 5'UTRs, such as SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 22, and SEQ ID NO: 23, which lack start codons, include a Kozak consensus sequence, and have point mutations to reduce secondary structure formation, enhancing translation efficiency.
The modified 5'UTRs significantly increase protein translation rates in various cell types, as demonstrated by luciferase expression assays, indicating improved translation efficiency and stability of mRNA therapeutics.
Smart Images

Figure 2024542318000001_ABST
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This patent application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 284,261, filed November 30, 2021, the contents of which are incorporated by reference in their entirety into this disclosure. [Background technology]
[0002] To efficiently translate proteins from mRNA, mRNA molecules contain several sequence or structural components, including a 5' cap, a 5' untranslated region (UTR), an open reading frame, a 3' untranslated region, and a polyadenylation tail. The 5' and 3' UTRs are unique regulators for protein translation, specifically, the 5' UTR regulates the translation rate, whereas the 3' UTR affects the rate of transcript degradation. As a regulator of translation rate, de novo discovery and design of the 5' UTR is an important consideration for the manufacturability and dosing of mRNA therapeutics. Summary of the Invention
[0003] In one aspect, the disclosure provides a modified 5'UTR comprising SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:22, or SEQ ID NO:23.
[0004] In another aspect, the disclosure provides a polynucleotide sequence comprising the 5'UTR of hist1h1c or rpl15, wherein the 5'UTR comprises one or more point mutations that reduce formation of a secondary structure in the 5'UTR.
[0005] In some embodiments of the polynucleotide sequence, the 5'UTR is the 5'UTR of hist1h1c, wherein the 5'UTR of hist1h1c lacks a start codon and comprises a Kozak consensus sequence at the 3' end of the 5'UTR of hist1h1c.
[0006] In some embodiments of the polynucleotide sequence, the 5'UTR of hist1h1c comprises substitution mutations at positions 6, 8, 26, 28, and 36 from the 5' end of the 5'UTR of hist1h1c.
[0007] In some embodiments of the polynucleotide sequence, the 5'UTR of hist1h1c further comprises substitution mutations at positions 4, 5, 25, 27, 32, 33, 34, 41, and 42 from the 5' end of the 5'UTR of hist1h1c.
[0008] In some embodiments of the polynucleotide sequence, the 5'UTR of hist1h1c further comprises a substitution mutation at position 13 from the 5' end of the 5'UTR of hist1h1c.
[0009] In some embodiments of the polynucleotide sequence, the 5'UTR of hist1h1c further comprises a substitution mutation at position 13 from the 5' end of the 5'UTR of hist1h1c and an insertion mutation at the 5' end of the 5'UTR of hist1h1c. In some embodiments, the insertion mutation is immediately upstream of position 1 from the 5' end of the 5'UTR of hist1h1c. In some embodiments, the insertion mutation is a single nucleotide insertion.
[0010] In some embodiments of the polynucleotide sequence, the 5'UTR is the 5'UTR of rpl15, which lacks a start codon and contains a Kozak consensus sequence at the 3' end of the 5'UTR of hist1h1c.
[0011] In some embodiments of the polynucleotide sequence, the 5'UTR of rpl15 comprises substitution mutations at positions 11, 13, 14, 15, 24, and 26 from the 5' end of the 5'UTR of rpl15.
[0012] In some embodiments of the polynucleotide sequence, the 5'UTR of rpl15 further comprises substitution mutations at positions 25 and 27 from the 5' end of the 5'UTR of rpl15.
[0013] In some embodiments of the polynucleotide sequence, the 5'UTR of rpl15 further comprises substitution mutations at positions 12, 16, and 23 from the 5' end of the 5'UTR of rpl15.
[0014] In some embodiments of the polynucleotide sequence, the 5'UTR of rpl15 further comprises a substitution mutation at positions 25 and 27 from the 5' end of the 5'UTR of rpl15, and an insertion mutation at the 5' end of the 5'UTR of rpl15. In some embodiments, the insertion mutation is immediately upstream of position 1 from the 5' end of the 5'UTR of rpl15. In some embodiments, the insertion mutation is a single nucleotide insertion.
[0015] In some aspects of the polynucleotide sequence, the polynucleotide sequence further comprises a coding region located downstream of the 5'UTR of hist1h1c or rpl15. In some aspects, the polynucleotide sequence comprises a 5'UTR having a sequence selected from SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:22, or SEQ ID NO:23.
[0016] In another aspect, the disclosure provides a method of increasing translation of a target mRNA, comprising promoting translation with a modified 5'UTR comprising SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:22, or SEQ ID NO:23, wherein the modified 5'UTR is upstream of the target mRNA in a polynucleotide sequence.
[0017] In yet another aspect, the disclosure provides a method of increasing translation of a target mRNA, comprising promoting translation with a modified 5'UTR of hist1h1c or rpl15, wherein the 5'UTR comprises one or more point mutations that reduce formation of secondary structures in the 5'UTR, and wherein the modified 5'UTR is upstream of the target mRNA in nucleotide sequence.
[0018] In some embodiments of the method, the 5'UTR is the 5'UTR of hist1h1c, wherein the 5'UTR of hist1h1c lacks a start codon and comprises a Kozak consensus sequence at the 3' end of the 5'UTR of hist1h1c.
[0019] In some embodiments of the method, the 5'UTR of hist1h1c comprises substitution mutations at positions 6, 8, 26, 28, and 36 from the 5' end of the 5'UTR of hist1h1c.
[0020] In some embodiments of the method, the 5'UTR of hist1h1c further comprises substitution mutations at positions 4, 5, 25, 27, 32, 33, 34, 41, and 42 from the 5' end of the 5'UTR of hist1h1c.
[0021] In some embodiments of the method, the 5'UTR of hist1h1c further comprises a substitution mutation at position 13 from the 5' end of the 5'UTR of hist1h1c.
[0022] In some aspects of the method, the 5'UTR of hist1h1c further comprises a substitution mutation at position 13 from the 5' end of the 5'UTR of hist1h1c and an insertion mutation at the 5' end of the 5'UTR of hist1h1c. In some aspects, the insertion mutation is immediately upstream of position 1 from the 5' end of the 5'UTR of hist1h1c. In some aspects, the insertion mutation is a single nucleotide insertion.
[0023] In some embodiments of the method, the 5'UTR is the 5'UTR of rpl15, which lacks a start codon and contains a Kozak consensus sequence at the 3' end of the 5'UTR of hist1h1c.
[0024] In some embodiments of the method, the 5'UTR of rpl15 comprises substitution mutations at positions 11, 13, 14, 15, 24, and 26 from the 5' end of the 5'UTR of rpl15.
[0025] In some embodiments of this method, the 5'UTR of rpl15 further comprises substitution mutations at positions 25 and 27 from the 5' end of the 5'UTR of rpl15.
[0026] In some embodiments of the method, the 5'UTR of rpl15 further comprises substitution mutations at positions 12, 16, and 23 from the 5' end of the 5'UTR of rpl15.
[0027] In some aspects of the method, the 5'UTR of rpl15 further comprises a substitution mutation at positions 25 and 27 from the 5' end of the 5'UTR of rpl15, and an insertion mutation at the 5' end of the 5'UTR of rpl15. In some aspects, the insertion mutation is immediately upstream of position 1 from the 5' end of the 5'UTR of rpl15. In some aspects, the insertion mutation is a single nucleotide insertion.
[0028] Other aspects and features of the present disclosure will become apparent to those of ordinary skill in the art upon review of the following description of specific embodiments of the disclosure in conjunction with the accompanying figures.
[0029] It should be understood that all combinations of the foregoing concepts, and the additional concepts discussed in more detail below (provided that such concepts are not mutually inconsistent), are contemplated as being part of the inventive subject matter disclosed herein and may be employed to achieve the benefits described herein. [Brief description of the drawings]
[0030] [Figure 1A] 1 illustrates the resulting secondary RNA structure of the hist1h1c 5'UTR with the Kozak consensus sequence (SEQ ID NO:2) in one embodiment. [Figure 1B] 1 illustrates the resulting secondary RNA structure of hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 1 (SEQ ID NO:3) in one embodiment. [Figure 1C] 1 illustrates the resulting secondary RNA structure of hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 2 (SEQ ID NO:4) in one embodiment. [Figure 1D]1 illustrates the resulting secondary RNA structure of hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 3 (SEQ ID NO:5) in one embodiment. [Figure 1E] 1 illustrates the resulting secondary RNA structure of hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 4 (SEQ ID NO:6) in one embodiment. [Figure 1F] 1 illustrates the resulting secondary RNA structure of hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 5 (SEQ ID NO:7) in one embodiment. [Figure 1G] 1 illustrates the resulting secondary RNA structure of hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 6 (SEQ ID NO:8) in one embodiment. [Figure 1H] 1 illustrates the resulting secondary RNA structure of hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 7 (SEQ ID NO:9) in one embodiment. [Figure 1I] 1 illustrates the resulting secondary RNA structure of the hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 8 (SEQ ID NO: 10) in one embodiment. [Figure 1J] 1 illustrates the resulting secondary RNA structure of hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 10 (SEQ ID NO: 12) in one embodiment. [Figure 1K] 1 illustrates the resulting secondary RNA structure of hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 11 (SEQ ID NO: 13) in one embodiment. [Figure 1L] 1 illustrates the resulting secondary RNA structure of hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 12 (SEQ ID NO: 14) in one embodiment. [Figure 1M]1 illustrates the resulting secondary RNA structure of hist1h1c 5'UTR with a Kozak consensus sequence and point mutations according to variant 13 (SEQ ID NO: 15) in one embodiment. [Figure 2A] 1 illustrates the resulting secondary RNA structure of the rpl15 5'UTR with the Kozak consensus sequence (SEQ ID NO: 18) in one embodiment. [Figure 2B] 1 illustrates the resulting secondary RNA structure of rpl15 5'UTR with the Kozak consensus sequence and point mutations according to variant 14 (SEQ ID NO: 19) in one embodiment. [Figure 2C] 2 illustrates the resulting secondary RNA structure of rpl15 5'UTR with the Kozak consensus sequence and point mutations according to variant 15 (SEQ ID NO:20) in one embodiment. [Figure 2D] 2 illustrates the resulting secondary RNA structure of rpl15 5'UTR with the Kozak consensus sequence and point mutations according to variant 16 (SEQ ID NO:21) in one embodiment. [Figure 2E] 2 illustrates the resulting secondary RNA structure of rpl15 5'UTR with the Kozak consensus sequence and point mutations according to variant 17 (SEQ ID NO:22) in one embodiment. [Figure 2F] 1 illustrates the resulting secondary RNA structure of rpl15 5'UTR with the Kozak consensus sequence and point mutations according to variant 18 (SEQ ID NO:23) in one embodiment. [Diagram 3] 1 is a graph depicting the time course of luciferase expression in HEK293 cells transfected with an expression vector comprising a modified 5'UTR of the present disclosure, in one embodiment. [Figure 4] 1 is a graph depicting luciferase expression 12 hours post-transfection in JAWSII cells transfected with an expression vector comprising a modified 5'UTR of the present disclosure, in one embodiment. [Diagram 5]1 is a graph depicting the time course of luciferase expression in PBMCs transfected with an expression vector comprising a modified 5'UTR of the present disclosure, in one embodiment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] term Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this disclosure pertains. For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press, The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press, and Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press provide those of ordinary skill in the art with a general dictionary of many of the terms used in this disclosure.
[0032] Expression: As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription), (2) processing of the RNA transcript (e.g., by splicing, editing, 5' capping, and / or 3' end processing), (3) translation of the RNA into a polypeptide or protein, and (4) post-translational modification of the polypeptide or protein.
[0033] Identity: As used herein, the term "identity" refers to the overall monomer conservation between polymer molecules, e.g., between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. Calculation of percent identity of two polynucleotide sequences can be performed, for example, by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of the first and second nucleic acid sequences for optimal alignment, and non-identical sequences can be ignored for comparison purposes). In certain embodiments, the length of the sequence aligned for comparison purposes is at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. If a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences. Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. When comparing DNA and RNA, thymine (T) and uracil (U) can be considered equivalent.
[0034] Suitable software programs are available from various sources for alignment of both protein and nucleotide sequences. One suitable program for determining percent identity of sequences is bl2seq, which is part of the BLAST suite of programs available from the BLAST website of the U.S. Government's National Center for Biotechnology Information (blast.ncbi.nlm.nih.gov). Bl2seq performs comparisons between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other suitable programs are, for example, Needle, Stretcher, Water, or Matcher, which are part of the EMBOSS suite of bioinformatics programs and are also available from the European Bioinformatics Institute (EBI).
[0035] Sequence alignment can be performed using methods such as, but not limited to, MAFFT, Clustal (ClustalW, Clustal X, or Clustal Omega), or MUSCLE.
[0036] Different regions within a single polynucleotide or polypeptide target sequence that are aligned with a polynucleotide or polypeptide reference sequence can each have their own percent sequence identity.
[0037] In vitro: As used herein, "in vitro" refers to events that take place not in a living organism (e.g., an animal, plant, or microorganism) but in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a petri dish, etc.
[0038] In vivo: As used herein, "in vivo" refers to events that take place within an organism (e.g., an animal, plant, or microorganism, or cells or tissues thereof).
[0039] Isolated: As used herein, the term "isolated" refers to a substance or entity that is separated from at least some of the components with which it is associated (whether in nature or in an experimental setting). Isolated substances (e.g., nucleotide sequences or protein sequences) can have various levels of purity with respect to the substances with which they are associated. Isolated substances and / or entities can be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more of the other components with which they were originally associated. In some embodiments, an isolated agent is more than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is "pure" if it is substantially free of other components. The term "substantially isolated" means that the compound is substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compound of the present disclosure. Substantial separation can include a composition that contains at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, or at least about 99% by weight of the compound of the present disclosure or a salt thereof.
[0040] An "isolated" polynucleotide, vector, polypeptide, cell, or any composition disclosed herein is a polynucleotide, vector, polypeptide, cell, or composition that is in a form not found in nature. Isolated polynucleotides, vectors, polypeptides, or compositions include those that have been purified to the extent that they are no longer in the form in which they are found in nature. In some aspects, an isolated polynucleotide, vector, polypeptide, or composition is substantially pure.
[0041] Nucleotides are referred to by their commonly accepted single-letter codes. Unless otherwise indicated, nucleic acids are written left to right in a 5' to 3' orientation. Nucleotides are referred to herein by their commonly known single-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Thus, A stands for adenine, C stands for cytosine, G stands for guanine, T stands for thymine, and U stands for uracil.
[0042] Messenger RNA (mRNA): As used herein, the term "messenger RNA" (mRNA) refers to any polynucleotide that encodes a polypeptide of interest and can be translated to produce the encoded polypeptide in vitro, in vivo, in situ, or ex vivo.
[0043] Natural or Naturally Occurring: As used herein, "natural" or "naturally occurring" polynucleotide sequence refers to a polynucleotide sequence that occurs in nature without the aid of artificial means.
[0044] Nucleic acid sequence: The terms "nucleic acid sequence," "nucleotide sequence," or "polynucleotide sequence" are used interchangeably and refer to a contiguous nucleic acid sequence. This sequence can be either single- or double-stranded DNA or RNA (e.g., mRNA).
[0045] The term "nucleic acid" in its broadest sense includes any compound and / or substance that contains a polymer of nucleotides. These polymers are often referred to as polynucleotides. Examples of nucleic acids or polynucleotides of the present disclosure include, but are not limited to, ribonucleic acid (RNA) or deoxyribonucleic acid (DNA).
[0046] The phrase "encoding nucleotide sequence" refers to a nucleic acid (e.g., mRNA or DNA molecule) coding sequence that encodes a polypeptide. As used herein, the terms "coding region" and "coding sequence" refer to an open reading frame (ORF) in a polynucleotide that upon expression produces a polypeptide or protein. The coding sequence may further include initiation and termination signals operably linked to regulatory elements, including a promoter and polyadenylation signal capable of directing expression in cells of an individual or mammal to which the nucleic acid is administered. The coding sequence may further include a sequence encoding a signal peptide.
[0047] Open reading frame: As used herein, "open reading frame" or "ORF" refers to a sequence that does not contain a stop codon in a given reading frame.
[0048] Portion: As used herein, a "portion" or "region" of a polynucleotide is defined as any portion of a polynucleotide that is less than the full length of the polynucleotide. Similarly, a "portion" or "region" of a polypeptide is defined as any portion of a polypeptide that is less than the full length of the polynucleotide.
[0049] Point mutation: As used herein, "point mutation" refers to a genetic mutation in which a single nucleobase is replaced, inserted, or deleted from a polynucleotide sequence. As used herein, the term "nucleobase substitution," "substitution," or "substitution mutation" refers to the replacement of a single nucleobase present in a reference polynucleotide sequence (e.g., a wild-type or naturally occurring sequence) with another nucleobase. Thus, reference to a "substitution at position X" refers to the replacement of the nucleobase present at position X with an alternative nucleobase.
[0050] As used herein, a "nucleobase insertion," "insertion," or "insertion mutation" refers to the insertion of a single nucleobase immediately adjacent to a nucleobase at a particular position in a reference polynucleotide sequence. As used herein, a "nucleobase deletion," "deletion," or "deletion mutation" refers to the deletion of a single nucleobase immediately adjacent to a nucleobase at a particular position in a reference polynucleotide sequence.
[0051] Polynucleotide: As used herein, the term "polynucleotide" refers to a polymer of nucleotides of any length, including ribonucleotides, deoxyribonucleotides, their analogs, or mixtures thereof. The term refers to the primary structure of the molecule. Thus, the term includes triple-, double-, and single-stranded deoxyribonucleic acid ("DNA"), as well as triple-, double-, and single-stranded ribonucleic acid ("RNA"). More specifically, the term "polynucleotide" includes polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose) (including tRNA, rRNA, hRNA, siRNA, and mRNA, whether spliced or unspliced), any other type of polynucleotide that is an N- or C-glycoside of a purine or pyrimidine base, as well as other polymers that contain non-nucleotide backbones, such as polyamides (e.g., peptide nucleic acids "PNAs") and polymorpholino polymers, as well as other synthetic sequence-specific nucleic acid polymers. However, the polymer contains nucleobases in a configuration that allows for base pairing and base stacking as found in DNA and RNA. In certain embodiments, the polynucleotide comprises mRNA.
[0052] Although T bases in the codon maps disclosed herein are present in DNA, the T bases may be replaced by U bases in the corresponding RNA. For example, a codon-nucleotide sequence disclosed herein in DNA form, such as a vector or an in vitro translation (IVT) template, may have its T base transcribed as a U base in its corresponding transcribed mRNA. In this regard, both codon-optimized DNA sequences (including T) and their corresponding RNA sequences (including U) are considered codon-optimized nucleotide sequences of the present disclosure. Equivalent codon maps may be generated by replacing one or more bases with unnatural bases. Thus, for example, a TTC codon (DNA map) may correspond to a UUC codon (RNA map), which in turn may correspond to a "P"C codon (RNA map with U replaced with pseudouridine).
[0053] Standard AT and GC base pairs are formed under conditions that allow the formation of hydrogen bonds between the N3-H and C4-oxy of thymidine and the N1 and C6-NH2 of adenosine, respectively, and between the C2-oxy, N3 and C4-NH2 of cytidine and the C2-NH2, N'-H and C6-oxy of guanosine, respectively. Thus, for example, guanosine (2-amino-6-oxy-9-β-D-ribofuranosyl-purine) can be modified to form isoguanosine (2-oxy-6-amino-9-β-D-ribofuranosyl-purine). Such modifications result in nucleoside bases that no longer effectively form standard base pairs with cytosine. However, modification of cytosine (1-β-D-ribofuranosyl-2-oxy-4-amino-pyrimidine) to form isocytosine (1-β-D-ribofuranosyl-2-oxy-4-amino-pyrimidine-) results in a modified nucleotide that does not base pair efficiently with guanosine, but does base pair with isoguanosine.
[0054] Polypeptide: The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. Polymers can include modified amino acids. These terms also include amino acid polymers that are modified naturally or by intervention, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. For example, polypeptides containing one or more analogs of an amino acid, including, for example, homocysteine, ornithine, p-acetylphenylalanine, D-amino acids, and unnatural amino acids such as creatine, are also included within this definition.
[0055] The term, as used herein, refers to proteins, polypeptides, and peptides of any size, structure, or function. Polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments, and other equivalents, variants, and analogs of the foregoing. Polypeptides may be single polypeptides or multi-molecular complexes, such as dimers, trimers, or tetramers. They may also include single-chain or multi-chain polypeptides. Most commonly, disulfide bonds are found in multi-chain polypeptides. The term polypeptide may also apply to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids. In some embodiments, a "peptide" may be about 50 amino acids long or less, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.
[0056] Reference nucleic acid sequence: The term "reference nucleic acid sequence," "reference nucleic acid," or "reference nucleotide sequence" or "reference sequence" refers to a starting nucleic acid sequence (e.g., an RNA sequence, e.g., an mRNA sequence) that can be sequence optimized. In some embodiments, the reference nucleic acid sequence is a wild-type or naturally occurring nucleic acid sequence, a fragment or a variant thereof.
[0057] Sequence optimization: As used herein, "sequence optimization" refers to a process or set of processes in which nucleobases in a reference nucleic acid sequence are replaced with alternative nucleobases, resulting in a nucleic acid sequence with improved properties. In the context of the present disclosure, sequence optimization refers to modifications in the nucleotide sequence of a 5'UTR that result in improved translation of a downstream gene target when the 5'UTR is incorporated into a suitable expression system.
[0058] Similarity: As used herein, the term "similarity" refers to the overall relatedness between polymer molecules, e.g., between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. Calculation of the percent similarity of polymer molecules to each other can be performed similarly to calculation of percent identity, except that the calculation of percent similarity takes into account conservative substitutions.
[0059] Substantially: As used herein, the term "substantially" refers to a qualitative condition indicating the entire or nearly entire extent or degree of a feature or characteristic of interest. Biological and chemical phenomena rarely, if ever, proceed to completion and / or completeness, or achieve or avoid absolute results. Thus, the term "substantially" is used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena. For example, "substantially" can refer to within at least about 20%, alternatively at least about 10%, alternatively at least about 5% of a feature or characteristic of interest.
[0060] Synthetic: The term "synthetic" means produced, prepared, and / or manufactured by the hand of man. Synthesis of polynucleotides or other molecules of the disclosure can be chemical or enzymatic.
[0061] Terminal: As used herein, the term "terminal" refers to the end of a peptide or polypeptide when referring to a polypeptide. Such terminals are not limited to only the first or last site of a peptide or polypeptide, but may include additional amino acids in the terminal region. The polypeptide-based molecules of the present disclosure can be characterized as having both an N-terminus (terminated by an amino acid having a free amino group (NH2)) and a C-terminus (terminated by an amino acid having a free carboxyl group (COOH)). Proteins of the present disclosure are optionally composed of multiple polypeptide chains held together by disulfide bonds or non-covalent forces (multimers, oligomers). These types of proteins have multiple N- and C-termini. Alternatively, the termini of a polypeptide can be optionally modified to begin or end with a non-polypeptide-based moiety, such as an organic conjugate.
[0062] Transfection: As used herein, "transfection" refers to the introduction of a polynucleotide into a cell, where a polypeptide encoded by the polynucleotide is expressed (e.g., mRNA) or where the polypeptide modulates a cellular function (e.g., siRNA, miRNA). As used herein, "expression" of a nucleic acid sequence refers to the translation of a polynucleotide (e.g., mRNA) into a polypeptide or protein and / or the post-translational modification of a polypeptide or protein.
[0063] Unmodified: As used herein, "unmodified" refers to any substance, compound, or molecule before it has been changed in any way. Unmodified can, but does not always, refer to the wild-type or native form of a biomolecule. A molecule can undergo a series of modifications, whereby each modified molecule can serve as the "unmodified" starting molecule for subsequent modifications.
[0064] Untranslated Region: As used herein, "untranslated region" or "UTR" refers to regions located at the 5' and 3' ends of an mRNA construct that do not form part of the protein coding region. The 5'UTR is upstream of the coding sequence.
[0065] Modified 5'UTR Described herein are examples of polynucleotide sequences, more specifically, 5'UTRs derived from the 5'UTR of hist1h1c (i.e., "modified hist1h1c 5'UTR") or rpl15 5'UTR (i.e., "modified rpl15 5'UTR"). The modified 5'UTRs, when incorporated into an expression construct or vector, can be used to promote expression of a target polynucleotide (e.g., a target mRNA). As used herein, a "modified" 5'UTR refers to a 5'UTR sequence resulting from sequence optimization.
[0066] In one aspect, the polynucleotide sequences making up the modified 5'UTRs of the present disclosure share the following characteristics: a. derived from the native 5'UTR of hist1h1c or rpl15, b. the absence of one or more stop codons; c. Absence of the 5'-terminal oligopyrimidine tract (5'TOP) inhibitory motif; d. the presence of a Kozak consensus sequence at the 3' end; and e. The presence of one or more point mutations that prevent, or at least reduce, the formation of secondary structure in the 5'UTR.
[0067] In some embodiments, the modified 5'UTR comprises a polynucleotide sequence shown in Table 1.
[0068] [Table 1]
[0069] In exemplary embodiments, the modified 5'UTR comprises SEQ ID NO:15 or SEQ ID NO:23.
[0070] In some embodiments, the modified 5'UTR comprises a combination of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 22, and / or SEQ ID NO: 23. In some embodiments, the modified 5'UTR comprises a combination of SEQ ID NO: 15 and SEQ ID NO: 23. In some embodiments, the modified 5'UTR comprises SEQ ID NO: 23.
[0071] In some embodiments, the 5'UTR is a modified hist1h1c 5'UTR comprising one or more point mutations that reduce the formation of secondary structures in the 5'UTR.
[0072] In some embodiments, the modified hist1h1c 5'UTR lacks all start codons.
[0073] In some embodiments, the modified hist1h1c 5'UTR lacks the 5'TOP inhibitory motif.
[0074] In some embodiments, the modified hist1h1c 5'UTR has a Kozak consensus sequence at the 3' end.
[0075] In some embodiments, the modified hist1h1c 5'UTR comprises substitution mutations at positions 6, 8, 26, 28, and 36 from the 5' end of the 5'UTR.
[0076] In some embodiments, the modified hist1h1c 5'UTR comprises substitution mutations at positions 4, 5, 6, 8, 25, 26, 27, 28, 32, 33, 34, 36, 41, and 42 from the 5' end of the 5'UTR. In some embodiments, the modified hist1h1c 5'UTR comprises substitution mutations at positions 6, 8, 13, 26, 28, and 36 from the 5' end of the 5'UTR.
[0077] In some embodiments, the modified hist1h1c 5'UTR comprises an insertion mutation at the 5' end of the 5'UTR, where the insertion is immediately upstream of (ie, preceding) position 1 from the 5' end of the 5'UTR.
[0078] In some embodiments, the polynucleotide sequence making up the modified hist1h1c 5'UTR is characterized by: A lack of a start codon b. Absence of the 5'TOP inhibitory motif; c. the presence of a Kozak consensus sequence at the 3' end; and d. Presence of substitution mutations at positions 6, 8, 26, 28, and 36 from the 5' end of the 5'UTR.
[0079] In some embodiments, the polynucleotide sequence making up the modified hist1h1c 5'UTR is characterized by: A lack of a start codon b. Absence of the 5'TOP inhibitory motif; c. the presence of a Kozak consensus sequence at the 3' end; and 4th, 5th, 6th, 8th, 25th, 26th, 27th, 28th, 32nd, 33rd, 34th from the 5' end of d.5'UTR, The presence of substitution mutations at positions 36, 41, and 42.
[0080] In some embodiments, the polynucleotide sequence making up the modified hist1h1c 5'UTR is characterized by: A lack of a start codon b. Absence of the 5'TOP inhibitory motif; c. the presence of a Kozak consensus sequence at the 3' end; and d. Presence of substitution mutations at positions 6, 8, 13, 26, 28, and 36 from the 5' end of the 5'UTR.
[0081] In some embodiments, the polynucleotide sequence making up the modified hist1h1c 5'UTR is characterized by: A lack of a start codon b. Absence of the 5'TOP inhibitory motif; c. the presence of a Kozak consensus sequence at the 3' end; d. The presence of substitution mutations at positions 6, 8, 13, 26, 28, and 36 from the 5' end of the 5'UTR; and e. The presence of an insertion mutation immediately upstream of position 1 from the 5' end of the 5'UTR.
[0082] In some embodiments, the 5'UTR is a modified rpl15 5'UTR comprising one or more point mutations that reduce the formation of secondary structures in the 5'UTR.
[0083] In some embodiments, the modified rpl15 5'UTR lacks all start codons.
[0084] In some embodiments, the modified rpl1 5'UTR lacks a 5'TOP inhibitory motif.
[0085] In some embodiments, the modified rpl1 5'UTR has a Kozak consensus sequence at the 3' end.
[0086] In some embodiments, the modified rpl15 5'UTR comprises substitution mutations at positions 11, 13, 14, 15, 24, and 26 from the 5' end of the 5'UTR.
[0087] In some embodiments, the modified rpl15 5'UTR comprises substitution mutations at positions 11, 13, 14, 15, 24, 25, 26, and 27 from the 5' end of the 5'UTR.
[0088] In some embodiments, the modified rpl15 5'UTR comprises substitution mutations at positions 11, 12, 13, 14, 15, 16, 23, 24, and 26 from the 5' end of the 5'UTR.
[0089] In some embodiments, the modified rpl15 5'UTR comprises an insertion mutation at the 5' end of the 5'UTR, the insertion being immediately upstream of (ie, preceding) position 1 from the 5' end of the 5'UTR.
[0090] In some embodiments, the polynucleotide sequence making up the modified rpl15 5'UTR is characterized by the following: A lack of a start codon b. Absence of the 5'TOP inhibitory motif; c. the presence of a Kozak consensus sequence at the 3' end; and d. The presence of substitution mutations at positions 11, 13, 14, 15, 24, and 26 from the 5' end of the 5'UTR.
[0091] In some embodiments, the polynucleotide sequence making up the modified rpl15 5'UTR is characterized by the following: A lack of a start codon b. Absence of the 5'TOP inhibitory motif; c. the presence of a Kozak consensus sequence at the 3' end; and d. Presence of substitution mutations at positions 11, 13, 14, 15, 24, 25, 26, and 27 from the 5' end of the 5'UTR.
[0092] In some embodiments, the polynucleotide sequence making up the modified rpl15 5'UTR is characterized by the following: A lack of a start codon b. Absence of the 5'TOP inhibitory motif; c. the presence of a Kozak consensus sequence at the 3' end; and d. 11, 12, 13, 14, 15, 16, 23, 24, and Presence of a substitution mutation at position 26.
[0093] In some embodiments, the polynucleotide sequence making up the modified rpl15 5'UTR is characterized by the following: A lack of a start codon b. Absence of the 5'TOP inhibitory motif; c. the presence of a Kozak consensus sequence at the 3' end; d. The presence of substitution mutations at positions 11, 13, 14, 15, 24, 25, 26, and 27 from the 5' end of the 5'UTR; and e. The presence of an insertion mutation immediately upstream of position 1 from the 5' end of the 5'UTR.
[0094] Methods for increasing translation efficiency In another aspect, the present disclosure provides a method of expressing a target polynucleotide (e.g., mRNA) with the modified 5'UTR described herein. In some aspects, the modified 5'UTR and the target polynucleotide can be operably linked to one or more regulatory nucleotide sequences in an expression construct. In some aspects, the nucleic acid sequences of the 5'UTR and the target polynucleotide can be expressed using a vector having a regulatory nucleotide sequence. The regulatory nucleotide sequence can include a promoter sequence, a leader or signal sequence, a ribosome binding site, a transcription start and end sequence, a translation start and end sequence, and an enhancer sequence. A promoter herein can refer to a naturally occurring promoter and a hybrid promoter that combines elements of two or more promoters. Any suitable expression vector and suitable regulatory sequence can be selected and optimized for a particular host cell. Any suitable constitutive or inducible promoter is contemplated for use with the modified 5'UTR of the present disclosure. The expression construct can be present in the cell on an episome, such as a plasmid, or can be inserted into a chromosome.
[0095] In some aspects, the expression vector can contain a selectable marker gene for the selection of transformed host cells. The selectable marker gene can be selected for a particular host cell.
[0096] A host cell can be transfected with an expression vector comprising the modified 5'UTR and the target polynucleotide and cultured under conditions suitable for expression of the target polynucleotide product (e.g., protein). In one embodiment, the target protein can be isolated from the cells and / or cell culture medium using a suitable purification technique, such as ion exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification.
[0097] Suitable expression vectors include plasmids such as pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids, and pUC-derived plasmids for expression in prokaryotic cells such as E. coli. pcDNAI / amp, pcDNAI / neo, pRc / CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo, and pHyg-derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids such as pBR322 to facilitate replication and drug resistance selection in both prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as bovine papilloma virus (BPV-1) or Epstein-Barr virus (pHEBo, pREP-derived, and p205) can be used for transient expression of proteins in eukaryotic cells.
[0098] Creating a recombinant polynucleotide can involve joining various nucleic acid fragments encoding different polypeptide sequences or translational regulatory sequences.
[0099] In some embodiments, an expression vector comprising a modified 5'UTR of the present disclosure can be used to express a target polynucleotide in a host cell, such as a bacterial cell (e.g., E. coli), an insect cell (e.g., using a baculovirus expression system), yeast, or a mammalian cell. Other suitable host cells may be used. Thus, the present disclosure includes polynucleotides comprising a modified 5'UTR and a target polynucleotide, as well as host cells that express the polynucleotide.
[0100] In an exemplary embodiment, an expression construct comprises a modified 5'UTR of the present disclosure, an effector region encoding a protein (eg, an mRNA), and a 3'UTR.
[0101] In a further aspect, the present disclosure provides a method for increasing the translation of a target polynucleotide using the modified 5'UTR described herein. The method includes promoting the translation of a target polynucleotide having a modified 5'UTR, the 5'UTR being upstream of the target polynucleotide in the polynucleotide sequence. A polynucleotide and / or a host cell comprising the modified 5'UTR and the target polynucleotide described herein can be utilized in a method for increasing the translation of a target polynucleotide.
[0102] Example 3 and Figures 3-5 are non-limiting examples of increasing translation of a target polynucleotide using a modified 5'UTR according to one embodiment of the present disclosure.
[0103] composition In yet another aspect, the disclosure provides a composition comprising a polynucleotide or a host cell that expresses a polynucleotide described herein (i.e., a polynucleotide comprising a modified 5'UTR and a target polynucleotide).
[0104] In some embodiments, the composition is a therapeutic composition that includes one or more pharma- ceutically acceptable carriers, diluents, or excipients such as salts, buffers, preservatives, antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes, emollients, emulsifiers, fillers, film formers or coatings, flavors, fragrances, glidants, lubricants, adsorbents, suspending or dispersing agents, sweeteners, water of hydration, and / or other therapeutic agents.
[0105] In some aspects, the compositions include an expression construct comprising a modified 5'UTR of the disclosure, an effector region encoding a protein (eg, an mRNA), and a 3'UTR.
[0106] In some aspects, the therapeutic compositions can be used to treat a disease or disorder in a subject. In some aspects, the therapeutic compositions can be used to prevent a disease or disorder in a subject.
[0107] kit Another aspect of the disclosure is a kit comprising a modified 5'UTR, composition, polynucleotide, expression construct, or host cell described herein, and instructions or a label directing appropriate use or administration. Typically, the kit contains components in amounts and / or numbers sufficient to allow a user to administer one or more treatments to a subject and / or perform one or more experiments.
[0108] In some embodiments, the kit may include additional components for conducting research assays and / or for administering a therapeutically effective amount of the polynucleotide.
[0109] In some embodiments, the kit may include instructions for cloning the modified 5'UTR into an expression construct to encode a target polypeptide.
[0110] In some embodiments, the kits include an expression construct comprising a modified 5'UTR of the disclosure, an effector region encoding a protein (eg, mRNA), and a 3'UTR.
[0111] In some aspects, the kit may include instructions for producing the polypeptide, for example, by culturing a host cell described herein.
[0112] Equivalence and Scope In the claims, articles such as "a," "an," and "the" can mean one or more, unless indicated to the contrary or clear from the context. A claim or description containing "or" between one or more members of a group is deemed to be satisfied if one, more than one, or all of the members of the group are present in, employed in, or relevant to a given product or process, unless indicated to the contrary or clear from the context. The present disclosure includes embodiments in which exactly one member of a group is present in, employed in, or relevant to a given product or process. The present disclosure includes embodiments in which two or more, or all, of the members of a group are present in, employed in, or relevant to a given product or process.
[0113] As used herein, "about" used in connection with a numerical value throughout this specification and / or claims refers to an interval of precision. Typically, such an interval of precision is ±10%. "Approximately" as applied to one or more values of interest refers to a value similar to the stated reference value. In certain embodiments, the term "approximately" refers to a range of values that falls within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater or less) of the stated reference value, unless otherwise stated or clear from the context (except where such number may exceed 100% of possible values).
[0114] It is also noted that the term "comprising" is intended to be open-ended, permitting, but not requiring, the inclusion of additional elements or steps. When the term "comprising" is used herein, the term "consisting of" is also included and disclosed.
[0115] Where ranges are given, the endpoints are included. Moreover, unless otherwise indicated or clear from the context, it is to be understood that values expressed as ranges can assume any specific value or subrange within the ranges described in different aspects of this disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
[0116] The words that have been used are words of description rather than of limitation, and it is to be understood that changes may be made within the purview of the appended claims without departing from the true scope and spirit of the present disclosure in its broader aspects.
[0117] While the present disclosure has been described at some length and in some detail with respect to certain illustrated aspects, the present disclosure should not be limited to any such details or aspects or to any particular aspect, but rather should be construed with reference to the appended claims in a manner that provides the broadest possible interpretation of such claims in view of the prior art and thus effectively encompasses the intended scope of the present disclosure.
[0118] Furthermore, "and / or," as used herein, should be construed as a specific disclosure of each of the two specified features or components, with or without the other. Thus, the term "and / or" used herein in phrases such as "A and / or B" is intended to include "A and B," "A or B," "A" (single), and "B" (single). Similarly, the term "and / or" used in phrases such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).
[0119] Whenever an embodiment is described herein with the word "comprising," other similar embodiments are also provided that are described with the terms "consisting of" and / or "consisting essentially of."
[0120] Units, prefixes, and symbols are expressed in the format accepted by the International System of Units (SI). Numeric ranges include the numbers that define the range. When a range of values is listed, it is understood that each intervening integer value between the upper and lower recited limits of that range and each fraction thereof is also specifically disclosed, along with each subrange between such values. The upper and lower limits of any range can be independently included or excluded from the range, and each range in which either, neither, or both limits are included is also encompassed within the disclosure. When values are explicitly listed, it is understood that values that are approximately the same quantity or volume as the recited value are also within the scope of the disclosure. When combinations are disclosed, each subcombination of the elements of the combination is also specifically disclosed and is within the scope of the disclosure. Conversely, when different elements or groups of elements are individually disclosed, the combinations are also disclosed. When any element of the disclosure is disclosed as having multiple alternatives, examples of that disclosure in which each alternative is excluded, either alone or in any combination with the other alternatives, are also hereby disclosed. Two or more elements of the disclosure may have such exclusions, and all combinations of the elements having such exclusions are hereby disclosed.
[0121] The present disclosure is further illustrated by the following non-limiting examples. EXAMPLES
[0122] Example 1: Discovery of 5'UTR To identify candidate 5'UTRs, genes with high translation rates were searched for utilizing JMP statistical software. This initial search criteria identified approximately 5000 candidate genes. These candidates were then classified by the size of their respective 5'UTRs using UTRdb (ITB-INSTITUTE FOR BIOMEDICAL TECHNOLOGIES). Genes with 5'UTRs greater than 60 nucleobases were excluded from further investigation as 5'UTRs less than 60 nucleobases allowed for rapid DNA template synthesis using PCR. This resulted in 50 candidates, which were then screened for cellular expression using the Human Protein Atlas. From these 50 candidates, 9 candidates showed expression profiles characterized by low cell specificity and / or high expression in peripheral blood mononuclear cells (PBMCs). Two 5'UTR gene candidates, hist1h1c and rpl15, were selected for further investigation. Table 2 summarizes the initial gene screen.
[0123] [Table 2]
[0124] Example 2: De novo synthesis of 5'UTR De novo synthesis of the 5'UTR began with the removal of inhibitory motifs and start codons (e.g., ATG) from the native 5'UTR nucleotide sequences of hist1h1c and rpl15. Specifically, the 5'-terminal oligopyrimidine tract (5'TOP) inhibitory motifs containing cytosine and thymine / uracil repeats were removed. In addition, a Kozak consensus sequence (i.e., GCCACC) was added to the 3' end of the 5'UTR. Next, one or more point mutations were introduced into the 5'UTR of hist1h1c and rpl15 to reduce the formation of secondary structures in the 5'UTR.
[0125] Below, Table 3 summarizes the de novo synthesis of the hist1h1c 5'UTR. As shown in SEQ ID NO:1 (the native hist1h1c 5'UTR), removal of the 5'TOP was not required. Following addition of the Kozak consensus sequence (SEQ ID NO:2), one or more point mutations (i.e., single nucleobase substitutions, insertions, or deletions) were introduced into the nucleotide sequence (SEQ ID NOs:3-15). In each sequence in Table 3, the nucleobases of the Kozak consensus sequence are underlined, nucleobases representing substitutions are bold and underlined, and nucleobases representing insertions are bold and italicized.
[0126] Table 4 summarizes the de novo synthesis of the rpl15 5'UTR. The native rpl15 5'UTR (SEQ ID NO: 16) required removal of the 5'TOP, resulting in SEQ ID NO: 17. The native rpl15 5'UTR sequence contained the Kozak consensus sequence "GCCA" and the terminal Kozak consensus sequence "CC" was added to the 3' end of the rpl15 5'UTR (SEQ ID NO: 18) via nucleobase pair substitution. Following addition of the Kozak consensus sequence, one or more point mutations were introduced into the nucleotide sequence (SEQ ID NOs: 19-23). In each sequence in Table 4, the nucleobases of the Kozak consensus sequence are underlined, nucleobases representing substitutions are bold and underlined, and nucleobases representing insertions are bold and italicized.
[0127] The resulting free energies of the modified hist1h1c and rpl15 5'UTR are shown in Tables 5 and 6, respectively. The resulting structures of the modified hist1h1c and rpl15 5'UTR are shown in Figures 1A-1M and 2A-2F, respectively.
[0128] [Table 3]
[0129] [Table 4]
[0130] [Table 5]
[0131] [Table 6]
[0132] Example 3: Luciferase reporter assay To evaluate the expression activity of UTR2-UTR7, each UTR polynucleotide was PCR amplified and cloned into a luciferase expression vector. HEK293 cells, JAWSII (immortalized mouse immature dendritic cell line), and PBMCs were independently transfected with UTR1 (control UTR sequence), UTR2, UTR3, UTR4, UTR5, UTR6, or UTR7, and luciferase expression was measured at 3, 6, 12, and 30 hours. Figure 3 shows the luciferase expression (RLU) of transfected HEK293 cells over 30 hours. Figure 4 shows the luciferase expression of transfected JAWSII cells at 12 hours. Figure 5 shows the luciferase expression of transfected PBMCs over 30 hours. As shown in Figure 3, UTRs 2, 3, 4, 6 and 7 show increased relative luminescence units compared to the control UTR sequence, indicating increased translation when these UTR polynucleotides are transfected into HEK293 cells. As shown in Figures 4 and 5, UTRs 2-7 show increased relative luminescence units compared to the control UTR sequence, also indicating increased translation when these UTR polynucleotides are transfected into JAWSII cells and PBMCs.
[0133] [Table 7]
[0134] [Table 8]
Claims
1. A modified 5'UTR comprising SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:22, or SEQ ID NO:
23.
2. A polynucleotide sequence comprising a 5'UTR of hist1h1c or rpl15, said 5'UTR comprising one or more point mutations that reduce formation of a secondary structure in said 5'UTR.
3. 3. The polynucleotide sequence of claim 2, wherein the 5'UTR is the 5'UTR of hist1h1c, the 5'UTR of hist1h1c lacking a start codon and comprising a Kozak consensus sequence at the 3' end of the 5'UTR of hist1h1c.
4. 4. The polynucleotide sequence of claim 3, wherein the 5'UTR of hist1h1c comprises substitution mutations at positions 6, 8, 26, 28, and 36 from the 5' end of the 5'UTR of hist1h1c.
5. The polynucleotide sequence of claim 4, wherein the 5'UTR of hist1h1c further comprises substitution mutations at positions 4, 5, 25, 27, 32, 33, 34, 41, and 42 from the 5' end of the 5'UTR of hist1h1c.
6. 5. The polynucleotide sequence of claim 4, wherein the 5'UTR of hist1h1c further comprises a substitution mutation at position 13 from the 5' end of the 5'UTR of hist1h1c.
7. The polynucleotide sequence of claim 6, further comprising an insertion mutation at the 5' end of the 5'UTR of hist1h1c.
8. The polynucleotide sequence of claim 7, wherein the insertion mutation is immediately upstream of position 1 from the 5' end of the 5'UTR of the hist1h1c.
9. 9. The polynucleotide sequence of claim 8, wherein the insertion mutation is a single nucleotide insertion.
10. 3. The polynucleotide sequence of claim 2, wherein the 5'UTR is the 5'UTR of rpl15, the 5'UTR of rpl15 lacking a start codon and comprising a Kozak consensus sequence at the 3' end of the 5'UTR of hist1h1c.
11. 11. The polynucleotide sequence of claim 10, wherein the 5'UTR of rpl15 comprises substitution mutations at positions 11, 13, 14, 15, 24, and 26 from the 5' end of the 5'UTR of rpl15.
12. 12. The polynucleotide sequence of claim 11, wherein the 5'UTR of rpl15 further comprises substitution mutations at positions 25 and 27 from the 5' end of the 5'UTR of rpl15.
13. 12. The polynucleotide sequence of claim 11, wherein the 5'UTR of rpl15 further comprises substitution mutations at positions 12, 16, and 23 from the 5' end of the 5'UTR of rpl15.
14. The polynucleotide sequence of claim 12, further comprising an insertion mutation at the 5' end of the 5'UTR of rpl15.
15. 15. The polynucleotide sequence of claim 14, wherein the insertion mutation is immediately upstream of position 1 from the 5' end of the 5'UTR of rpl15.
16. 16. The polynucleotide sequence of claim 15, wherein the insertion mutation is a single nucleotide insertion.
17. The polynucleotide sequence of any one of claims 2 to 16, further comprising a coding region located downstream of the 5'UTR of said hist1h1c or said rpl15.
18. The polynucleotide sequence of any one of claims 2 to 17, wherein the 5'UTR comprises SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:22, or SEQ ID NO:
23.
19. A method for increasing translation of a target mRNA, the method comprising promoting translation using a modified 5'UTR comprising SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:22, or SEQ ID NO:23, wherein the modified 5'UTR is upstream of the target mRNA in a polynucleotide sequence.
20. A method for increasing translation of a target mRNA, the method comprising promoting translation using a modified 5'UTR of hist1h1c or rpl15, the 5'UTR comprising one or more point mutations that reduce formation of secondary structures in the 5'UTR, and the modified 5'UTR is upstream of the target mRNA in nucleotide sequence.
21. The method of claim 20, wherein the 5'UTR is the 5'UTR of the hist1h1c, the 5'UTR of the hist1h1c lacking a start codon and comprising a Kozak consensus sequence at the 3' end of the 5'UTR of the hist1h1c.
22. 22. The method of claim 21, wherein the 5'UTR of hist1h1c comprises substitution mutations at positions 6, 8, 26, 28 and 36 from the 5' end of the 5'UTR of hist1h1c.
23. 23. The method of claim 22, wherein the 5'UTR of hist1h1c further comprises substitution mutations at positions 4, 5, 25, 27, 32, 33, 34, 41, and 42 from the 5' end of the 5'UTR of hist1h1c.
24. 23. The method of claim 22, wherein the 5'UTR of hist1h1c further comprises a substitution mutation at position 13 from the 5' end of the 5'UTR of hist1h1c.
25. 25. The method of claim 24, further comprising an insertion mutation at the 5' end of the 5'UTR of the hist1h1c.
26. 26. The method of claim 25, wherein the insertion mutation is immediately upstream of position 1 from the 5' end of the 5'UTR of the hist1h1c.
27. 27. The method of claim 26, wherein the insertion mutation is a single nucleotide insertion.
28. 21. The method of claim 20, wherein the 5'UTR is the 5'UTR of rpl15, the 5'UTR of rpl15 lacking a start codon and comprising a Kozak consensus sequence at the 3' end of the 5'UTR of hist1h1c.
29. 29. The method of claim 28, wherein the 5'UTR of rpl15 comprises substitution mutations at positions 11, 13, 14, 15, 24, and 26 from the 5' end of the 5'UTR of rpl15.
30. 30. The method of claim 29, wherein the 5'UTR of rpl15 further comprises substitution mutations at positions 25 and 27 from the 5' end of the 5'UTR of rpl15.
31. 30. The method of claim 29, wherein the 5'UTR of rpl15 further comprises substitution mutations at positions 12, 16, and 23 from the 5' end of the 5'UTR of rpl15.
32. The method of claim 30, further comprising an insertion mutation at the 5' end of the 5'UTR of rpl15.
33. 33. The method of claim 32, wherein the insertion mutation is immediately upstream of position 1 from the 5' end of the 5'UTR of rpl15.
34. 34. The method of claim 33, wherein the insertion mutation is a single nucleotide insertion.
